Syremis Therapeutics

Sector: Healthcare & Life Sciences

About Syremis Therapeutics

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health.

Products

ST-905 is a potent M1/M4 muscarinic agonist currently in Phase 1. ST-905 is being developed for schizophrenia and other serious neuropsychiatric conditions. ST-901 is a novel NMDA antagonist currently in IND-enabling studies. ST-901 is being developed for major depressive disorder and bipolar depression.

Product page